The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Open accessAbstract
BACKGROUND Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD. METHODS This phase 3 open-label, randomized trial evaluated the efficacy and safety of ruxolitinib at a dose of 10 mg twice daily, as compared with the investigator's choice of therapy from a list of 10 commonly used options considered best available care (control), in patients 12 years of age or older with moderate or severe glucocorticoid-refractory or -dependent chronic GVHD. The primary end point was overall response (complete or partial response) at week 24; key secondary end points were failure-free survival and improved score on the modified Lee Symptom Scale at week 24. RESULTS A total of 329 patients underwent randomization; 165 patients were assigned to receive ruxolitinib and 164 patients to receive control therapy. Overall response at week 24 was greater in the ruxolitinib group than in the control group (49.7% vs. 25.6%; odds ratio, 2.99; P<0.001). Ruxolitinib led to longer median failure-free survival than control (>18.6 months vs. 5.7 months; hazard ratio, 0.37; P<0.001) and higher symptom response (24.2% vs. 11.0%; odds ratio, 2.62; P=0.001). The most common (occurring in ≥10% patients) adverse events of grade 3 or higher up to week 24 were thrombocytopenia (15.2% in the ruxolitinib group and 10.1% in the control group) and anemia (12.7% and 7.6%, respectively). The incidence of cytomegalovirus infections and reactivations was similar in the two groups. CONCLUSIONS Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was greater with ruxolitinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
Self-citationA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917635 · Cited by 881
Self-citationAdvances in graft-versus-host disease biology and therapy
Blazar, B. R., Murphy, W. J., & Abedi, M. (2012) · Nature Reviews Immunology · doi:10.1038/nri3212 · Cited by 880
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748
Self-citationLong-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation
Socié, G., Stone, J. V., Wingard, J. R., Weisdorf, D., Henslee-Downey, P. J., Bredeson, C., Cahn, J.-Y., Passweg, J. R., Rowlings, P. A., Schouten, H. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907013410103 · Cited by 698
Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
Wingard, J. R., Majhail, N. S., Brazauskas, R., Wang, Z., Sobocinski, K. A., Jacobsohn, D., Sorror, M. L., Horowitz, M. M., Bolwell, B., Rizzo, J. D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7212 · Cited by 632
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539
Self-citationIbrutinib for chronic graft-versus-host disease after failure of prior therapy
Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Blazar, B. R., et al. (2017) · Blood · doi:10.1182/blood-2017-07-793786 · Cited by 514
Lee, S. J., Wolff, D., Kitko, C., Koreth, J., Inamoto, Y., Jagasia, M., Pidala, J., Olivieri, A., Martin, P. J., Przepiorka, D., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.02.025 · Cited by 431
Self-citationActivity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Spoerl, S., Mathew, N. R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-543736 · Cited by 401
Self-citationPidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., Cutler, C., Jacobsohn, D., Palmer, J., Arai, S., et al. (2011) · Blood · doi:10.1182/blood-2010-11-319509 · Cited by 389
Self-citationJagasia, M., Perales, M.-A., Schroeder, M. A., Ali, H., Shah, N. N., Chen, Y.-B., Fazal, S., Dawkins, F. W., Arbushites, M. C., Tian, C., et al. (2020) · Blood · doi:10.1182/blood.2020004823 · Cited by 306
Schwab, L., Goroncy, L., Palaniyandi, S., Gautam, S., Triantafyllopoulou, A., Mocsai, A., Reichardt, W., Karlsson, F. J., Radhakrishnan, S. V., Hanke, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3517 · Cited by 302
Self-citationDevelopment and validation of a scale to measure symptoms of chronic graft-versus-host disease
Lee, S. J., Cook, E. F., Soiffer, R., & Antin, J. H. (2002) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2002.v8.pm12234170 · Cited by 246
Self-citationNicholson, S. E., Oates, A. C., Harpur, A. G., Ziemiecki, A., Wilks, A. F., & Layton, J. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2985 · Cited by 201
Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation
Arora, M., Cutler, C. S., Jagasia, M. H., Pidala, J., Chai, X., Martin, P. J., Flowers, M. E. D., Inamoto, Y., Chen, G. L., Wood, W. A., et al. (2016) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.10.018 · Cited by 186
Self-citationDiagnosis and management of chronic graft‐versus‐host disease
Dignan, F. L., Amrolia, P. J., Clark, A., Cornish, J., Jackson, G. H., Mahendra, P., Scarisbrick, J. J., Taylor, P. C., Shaw, B. E., & Potter, M. N. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09128.x · Cited by 158
Martin, P. J., Lee, S. J., Przepiorka, D., Horowitz, M. M., Koreth, J., Vogelsang, G. B., Walker, I., Carpenter, P. A., Griffith, L. M., Akpek, G., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.004 · Cited by 126
Self-citationKurosawa, S., Oshima, K., Yamaguchi, T., Yanagisawa, A., Fukuda, T., Kanamori, H., Mori, T., Takahashi, S., Kondo, T., Kohno, A., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.06.011 · Cited by 123
Self-citationHierarchical testing of multiple endpoints in group‐sequential trials
Glimm, E., Maurer, W., & Bretz, F. (2010) · Statistics in Medicine · doi:10.1002/sim.3748 · Cited by 89
Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD
Hechinger, A.-K., Smith, B. A. H., Flynn, R. P., Hanke, K., McDonald-Hyman, C. S., Taylor, P. A., Pfeifer, D., Hackanson, B. W., Leonhardt, F., Prinz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-581793 · Cited by 76
Self-citationPalmer, J. M., Chai, X., Pidala, J., Inamoto, Y., Martin, P. J., Storer, B. E., Pusic, I., Flowers, M. E. D., Arora, M., Pavletic, S. Z., et al. (2015) · Blood · doi:10.1182/blood-2015-08-662874 · Cited by 65
Self-citationMartin, P. J., Storer, B. E., Inamoto, Y., Flowers, M. E. D., Carpenter, P. A., Pidala, J., Palmer, J. M., Arora, M., Jagasia, M., Arai, S., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775767 · Cited by 60
Self-citationPolverelli, N., Palumbo, G. A., Binotto, G., Abruzzese, E., Benevolo, G., Bergamaschi, M., Tieghi, A., Bonifacio, M., Breccia, M., Catani, L., et al. (2018) · Hematological Oncology · doi:10.1002/hon.2509 · Cited by 59
Self-citationJacobs, J. M., Fishman, S., Sommer, R. K., Sereno, I., Fenech, A. L., Jankowski, A. L., Traeger, L. N., Greer, J. A., Vanderklish, J., Hunnewell, C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.024 · Cited by 51
Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale
Teh, C., Onstad, L., & Lee, S. J. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.020 · Cited by 41
Self-citationMerkel, E. C., Mitchell, S. A., & Lee, S. J. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.026 · Cited by 33
Self-citationPost-traumatic stress symptoms in hematopoietic stem cell transplant (HCT) recipients.
Griffith, S., Fenech, A. L., Nelson, A. M., Greer, J. A., Temel, J. S., & El-Jawahri, A. R. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.7505 · Cited by 8
Cited by
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Penack, O., Marchetti, M., Aljurf, M., Arat, M., Bonifazi, F., Duarte, R. F., Giebel, S., Greinix, H., Hazenberg, M. D., Kröger, N., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00342-3 · Cited by 262
Self-citation
Metadata
- Authors
- Zeiser, R., Polverelli, N., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., Hollaender, N., Gowda, M., Stefanelli, T., Lee, S. J., Teshima, T., & Locatelli, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-15
- Volume
- 385
- Issue
- 3
- Pages
- 228-238
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4247737273
- Cited by
- 527
- References
- 31
- FWCI
- 43.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.